Company Metrics

• 58.26 P/E
• 1.08 P/S
• 5.83 P/B
• -0.27 EPS
• -40.72% Cash ROIC
• 1.43 Cash Ratio
• 0.00 / N/A % Dividend
• 254,095.00 Avg. Vol.
• 88.90M Shares
• 37.1M Market Cap.

Company Description

Bioniche Life Sciences Inc., a biopharmaceutical company, engages in the development, manufacture, and marketing of proprietary products for human and animal health markets worldwide. The company operates three business units: Human Health, Animal Health, and Food Safety. The Human Health business unit develops proprietary human cancer therapies, with a focus on the research and development of the company's Mycobacterial Cell Wall-DNA Complex technology platform for the treatment of bladder and other cancers, and its oligonucleotides. It develops Urocidin that is in Phase III clinical trials for the treatment of non-muscle-invasive bladder cancer. The Animal Health business unit develops, manufactures, and markets animal health biopharmaceutical products. Its product portfolio comprises reproduction and embryo transfer products, products based on hyaluronans, immunostimulant products, polyclonal antibodies, vaccine products, and nutraceuticals that are marketed to veterinarians. The Food Safety business unit involves in researching, developing, manufacturing, and marketing veterinary biopharmaceutical products to enhance the safety of food and water supplies. This unit develops and commercializes Econiche, a cattle vaccine, which is used to reduce the spread of deadly E. coli O157 organism. The company was founded in 1979 and is headquartered in Belleville, Canada.
less

Bioniche Life Sciences Inc., a biopharmaceutical company, engages in the development, manufacture, and marketing of proprietary products for human and animal health markets worldwide. The company operates three business units: Human Health, Animal Health, and Food Safety. The Human Health business unit develops proprietary human cancer therapies, with a focus on the research and development of the...
more

News